Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).

NCT01151215 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01151215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01151215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2010
Completion date
January 31, 2013
Enrollment
482 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, neoplasms